Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma

Archives of Dermatology

Volumn 134, Issue 8, 1998, Pages 983-987

  Mraz Gernhard, Serena ^a   Sagebiel, Richard W ^a,b   Kashani Sabet, Mohammed ^a   Miller III, James R ^a,c   Leong, Stanley P L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SIZE; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SENTINEL LYMPH NODE;

EID: 0031904085     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.8.983     Document Type: Article

References (34)

1. Balch CM, Soong SSJ, Shaw HM, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, et al, eds. Cutaneous Melanoma. 2nd ed. Philadelphia, Pa: JB Lippincott Co; 1992:165-187.
2. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann Intern Med. 1996; 125:369-375.
3. Blois MS, Sagebiel RW, Abarbanel RM, Caldwell TM, Tuttle MS. Malignant melanoma of the skin: the association of tumor depth and type, and patient sex, age, and site with survival. Cancer. 1983;52:1330-1341.
4. Johnson KO, Emrich LJ, Karakousis CP, Rao U, Greco WR. Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical stage I. Cancer. 1985;55:1107-1117.
5. Sagebiel RW. The pathology of melanoma as a basis for prognostic models: the UCSF experience. Pigment Cell Res. 1994;7:101-103.
6. Halpern AC, Schuchter LM. Prognostic models in melanoma. Semin Oncol. 1997; 24(1 suppl 4):S2-S7.
7. Day CL, Mihm MC, Lew RA, et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51-3.99 mm): a conceptual model for tumor growth and metastasis. Ann Surg. 1982;195:35-43.
8. Cohen MH, Ketchum AS, Felix EL, et al. Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann Surg. 1977;186:635-642.
9. Balch CM, Murad TM, Soong SJ, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978;188:732-742.
10. Roses DF, Provet JA, Harris MN, Gumport SL, Dubin N. Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Ann Surg. 1984;201: 103-107.
11. Callery C, Cochran AJ, Roe DJ, et al. Factors prognostic for survival in patients with malignant melanoma spread to regional lymph nodes. Ann Surg. 1981;196: 69-75.
12. Ho VC, Sober AJ. Therapy for cutaneous melanoma: an update. J Am Acad Dermatol. 1990;22:159-176.
13. Reintgen D, Cruse W, Wey SK, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759-767.
14. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
15. Leong SP, Steinmetz I, Habib FA, et al. Optimal selective sentinel node dissection in primary malignant melanoma. Arch Surg. 1997;132:666-673.
16. Mudun A, Murray DR, Heran SC, et al. Early stage melanoma: lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe. Radiology. 1996;199:171-175.
17. van der Veen H, Hoekstra OS, Cuestra MA, Meijer S. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg. 1994;81:1769-1770.
18. Krag DN, Meijer SJ, Weaver DL, et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg. 1995;130:654-658.
19. Albertini JJ, Cruse CW, Rapaport D, et al. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg. 1996;223:217-224.
20. Sagebiel RW. The multidisciplinary melanoma center. Surg Clin North Am. 1996; 76:1433-1439.
21. Kelly JW, Sagebiel RW, Clyman S, Blois MS. Thin level IV malignant melanoma. Ann Surg. 1985;202:98-103.
22. Naruns P, Nizze J, Cochran A, Lee M, Morton D. Recurrence potential of thin primary melanomas. Cancer. 1986;57:545-548.
23. Vilmer C, Bailly C, Doussal V, et al. Thin melanomas with unusual aggressive behavior: a report of nine cases. J Am Acad Dermatol. 1996;34:439-444.
24. Rees WV, Robinson DS, Holmes EC, Morton DL. Altered lymphatic drainage following lymphadenectomy. Cancer. 1980;45:3045-3059.
25. Sagebiel RW. Pigmented lesion pathology: the specimen and its report: a personal and probably biased approach. In: LeBoit PE, eds. Pathology: State of the Art Reviews: Malignant Melanoma and Melanocytic Neoplasms. Philadelphia, Pa: Handley & Belfus Inc; 1994:281-298.
26. Crowley NJ, Seigler HF. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. Cancer. 1990;66:2522-2527.
27. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma, II: prognostic factors in patients with stage I (localized) melanoma. Surgery. 1979; 86:343-351.
28. Roses DF, Harris MN, Grumport SL, et al. Regional lymph node dissection for malignant melanoma of the extremities. Surgery. 1981;89:654-659.
29. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.
30. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15:1039-1051.
31. Spellman J, Driscoll D, Valez A, Karakousis C. Thick cutaneous melanoma of the trunk and extremities: an institutional review. Surg Oncol. 1994;3:335-343.
32. Silberman AW. Malignant melanoma: practical considerations concerning prophylactic regional lymph node dissection. Ann Surg. 1987;206:206-209.
33. Bear HD, Neifeld JP, Kay S. Prognosis of level V malignant melanoma. Cancer. 1985;55:1167-1171.
34. Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch Surg. 1990;125:322-326.